Search

Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.

We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.

Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.

• News

The aim of the site is to increase the level of awareness and understanding of genetic testing and genetic counselling among people living with inherited retinal dystrophies, empowering them to make fully informed decisions about their lives, healthcare and family planning.

Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.

• News

In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).

• News
• Usher syndrome

Thursday 2 July 2026, 7.00pm - 8.00pm - via Zoom - Please come and join our Glasgow group facilitator, Sarah Speed and Retina UK Ambassador, Colin Hetherington for a Summer online region-wide Scotland Peer Support Group meeting.

• Local Peer Support Group

Monday 11 May 2026, 7.00pm - 8.00pm - Via Zoom - Come and join James and the group for their latest online social catch up.

• Local Peer Support Group

Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.

• Webinar
• Audio
• Video

Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).

• News
• Retinitis pigmentosa